Natco Pharma plans to increase the production capacity and research & development activity at Rangareddy plant in Telangana, India that would generate 1, 500 jobs.
Natco Pharma plans to increase the production capacity and research & development activity at Rangareddy plant in Telangana.
The proposal is to increase the production capacity of 66 active pharmaceutical ingredients (APIs) and API intermediates at a time with research and development activity from 115.5 tonnes per annum (TPA) to 645 TPA in the existing land area of 34.17 hectare at Mekaguda village in Rangareddy district.
The project is expected to employ 1, 200 persons directly and 300 persons indirectly after the expansion. The company manufactures APIs in bulk quantities for both domestic and global markets.
Expansion of APIs and API intermediates manufacturing facility will not only increase the market availability of therapeutic drugs but also reduce the import burden on the country.
Its products are used in pharmaceutical formulation industry and manufacturing of therapeutic medicines like anti-depressant and anti-psychotic drugs, among others.
The expansion will be taking place in the existing land area, with an estimated project cost of $75 Million, including existing investment of around $49 Million, according to the approval by the Union Ministry of Environment, Forest and Climate Change.
The facility has been manufacturing three products and the proposal is to build capacities for another 66 products from which a select number of products will be manufactured in the facility, apart from a research and development facility.